Should I buy or sell Sosei Group stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sosei Group in the last year. There are currently 2 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "sell" SOLTF shares. View SOLTF analyst ratings or view top-rated stocks .

How have SOLTF shares performed in 2023?

Sosei Group's stock was trading at $15.5439 at the start of the year. Since then, SOLTF stock has decreased by 39.0% and is now trading at $9.48. View the best growth stocks for 2023 here .

Are investors shorting Sosei Group?

Sosei Group saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,062,100 shares, a decline of 29.0% from the October 31st total of 1,495,200 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 5,310.5 days. View Sosei Group's Short Interest .

How do I buy shares of Sosei Group?

Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Sosei Group Stock Price, News & Analysis (OTCMKTS:SOLTF)

$9.48

-0.47 (-4.72%)

(As of 12/4/2023 ET)

Compare

Today's Range: $9.48
▼
$9.71
50-Day Range: $8.93
▼
$10.41
52-Week Range: $8.93
▼
$22.78

Volume: 1,100 shs
Average Volume: 1,582 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

About Sosei Group Stock (OTCMKTS:SOLTF)

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

SOLTF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SOLTF Stock News Headlines

November 24, 2023 | finance.yahoo.com

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

November 14, 2023 | morningstar.com

Sosei Group Corp 4565

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 10, 2023 | msn.com

Sosei Group reports Q3 results

November 10, 2023 | finance.yahoo.com

Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases

November 10, 2023 | finance.yahoo.com

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

November 7, 2023 | finance.yahoo.com

Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023

November 5, 2023 | finance.yahoo.com

Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 31, 2023 | finance.yahoo.com

Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia

October 31, 2023 | finance.yahoo.com

Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership

October 25, 2023 | finance.yahoo.com

Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress

October 18, 2023 | finance.yahoo.com

Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023

October 10, 2023 | msn.com

Sosei and PharmEnable collaborate on another neurological drug

October 4, 2023 | finance.yahoo.com

Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development

September 20, 2023 | finance.yahoo.com

Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board

August 10, 2023 | finance.yahoo.com

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

August 4, 2023 | finance.yahoo.com

Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023

July 21, 2023 | reuters.com

Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 million - Nikkei

June 27, 2023 | marketwatch.com

Sosei Group Shares Indicated Lower After Partner Pfizer Terminates Diabetes Drug Development

June 3, 2023 | msn.com

Sosei Group (TYO:4565) Price Target Increased by 5.50% to 3,351.43

April 5, 2023 | finance.yahoo.com

Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

March 18, 2023 | finance.yahoo.com

Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market

December 22, 2022 | reuters.com

Sosei Group Corp

November 8, 2022 | finance.yahoo.com

PrecisionLife to Evaluate Precision Medicine Potential of Sosei Heptares Neuroscience GPCR Target

September 17, 2022 | investing.com

Sosei Group Corp (4565)

September 13, 2022 | msn.com

EXCLUSIVE | Ola Electric rejigs roles to unify operations across roles; YS Kim gets larger role

See More Headlines

Receive SOLTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sosei Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:SOLTF
CUSIP: N/A
CIK: N/A
Web: www.sosei.com
Phone: (135) 210-3290
Fax: N/A
Employees: 348
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Shinichi Tamura (Age 74)
Founder & Chairman of the Board
Comp: $1.54M
Mr. Christopher Cargill (Age 39)
Representative Executive Officer, President, CEO & Director
Comp: $1.32M
Mr. Hironoshin Nomura (Age 40)
Executive Officer, Executive VP & CFO
Mr. Kieran Johnson F.C.A. (Age 54)
Executive Officer, Executive VP & Chief Accounting Officer
Dr. Miles Congreve
Chief Scientific Officer
Mr. Kazuhiko Yoshizumi (Age 69)
Executive Officer, Executive VP & Chief Compliance Officer
Shinichiro Nishishita
VP of Investor Relations & Head of Regulatory Disclosures
Stacey Southall
Associate Director & Head of Biophysics
Ms. Candelle Chong (Age 34)
Executive Officer, Executive VP & Chief of Staff
Dr. Satoshi Tanaka
Executive Officer, Executive VP & President of Idorsia Pharmaceuticals Japan

Key Competitors

View All Competitors

SOLTF Stock Analysis - Frequently Asked Questions

Should I buy or sell Sosei Group stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sosei Group in the last year. There are currently 2 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "sell" SOLTF shares.
View SOLTF analyst ratings or view top-rated stocks.
How have SOLTF shares performed in 2023?: Sosei Group's stock was trading at $15.5439 at the start of the year. Since then, SOLTF stock has decreased by 39.0% and is now trading at $9.48.
View the best growth stocks for 2023 here.
Are investors shorting Sosei Group?: Sosei Group saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,062,100 shares, a decline of 29.0% from the October 31st total of 1,495,200 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 5,310.5 days.
View Sosei Group's Short Interest.
How do I buy shares of Sosei Group?: Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SOLTF) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial